These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22240597)

  • 1. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.
    Kataoka Y; Yasuda S; Miyamoto Y; Sase K; Kosuge M; Kimura K; Yoshimasa Y; Miyazaki S;
    Circ J; 2012; 76(3):712-20. PubMed ID: 22240597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: Insight from the DIANA study.
    Kataoka Y; Yasuda S; Miyamoto Y; Sase K; Kosuge M; Kimura K; Yoshimasa Y; Miyazaki S;
    J Atheroscler Thromb; 2014; 21(5):509-18. PubMed ID: 24430787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive glucose lowering in cardiovascular risk management - unsolved questions - .
    Shimabukuro M; Masuzaki H; Sata M
    Circ J; 2012; 76(3):593-5. PubMed ID: 22293455
    [No Abstract]   [Full Text] [Related]  

  • 4. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
    Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
    Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
    Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
    Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
    Kurebayashi S; Watada H; Tanaka Y; Kawasumi M; Kawamori R; Hirose T
    Endocr J; 2006 Apr; 53(2):213-7. PubMed ID: 16618980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of lowering postprandial glucose level on cardiovascular outcomes in early-stage diabetic patients with coronary artery disease: 10-year post-trial follow-up analysis of the DIANA study.
    Kataoka Y; Yasuda S; Asaumi Y; Honda S; Noguchi T; Miyamoto Y; Sase K; Iwahashi N; Kawamura T; Kosuge M; Kimura K; Takamisawa I; Iwanaga Y; Miyazaki S
    J Diabetes Complications; 2023 May; 37(5):108469. PubMed ID: 36996727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
    Mori Y; Kitahara Y; Miura K; Tajima N
    Endocrine; 2004 Feb; 23(1):39-43. PubMed ID: 15034195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control.
    Mita T; Watada H; Shimizu T; Tamura Y; Sato F; Watanabe T; Choi JB; Hirose T; Tanaka Y; Kawamori R
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2456-62. PubMed ID: 17872451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
    Hirose T; Mizuno R; Yoshimoto T
    Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
    Yamada K
    Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
    Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
    Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats.
    Ichikawa K; Yamato T; Ojima K; Tsuji A; Ishikawa K; Kusama H; Kojima M
    Clin Exp Pharmacol Physiol; 2002; 29(5-6):423-7. PubMed ID: 12010187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.